4 results
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
The primary objective is to explore the efficacy of nintedanib (as measured by progression free survival) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.
The primary objective of this study is to evaluate the safety and tolerability of intramuscular administration of the HIV-1 envelope protein ConM SOSIP.v7 gp140 vaccine, adjuvanted with MPLA liposomes, in HIV-uninfected adults. The secondary…
The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.